Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPI1 | P60174 | 2/20 | 0.50 |
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
| ▸ | PGK2 | P07205 | 1/20 | 0.38 |
| ▸ | PGD | P52209 | 3/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5485133 | 0.86 | TPI1 (0.56) | TPI1PGK1PGK2PGDLPAR3 | |
| SCHEMBL43277 | 0.79 | TPI1 (0.50) | TPI1PGK1PGK2PGDLPAR3 | |
| SCHEMBL28769882 | 0.77 | TPI1 (0.48) | TPI1PGK1PGK2PGDLPAR3 | |
| SCHEMBL28466527 | 0.77 | TPI1 (0.48) | TPI1PGK1PGK2PGDLPAR3 | |
| SCHEMBL8138239 | 0.77 | TPI1 (0.48) | TPI1PGK1PGK2PGDLPAR3 | |
| SCHEMBL1065797 | 0.77 | TPI1 (0.48) | TPI1PGK1PGK2PGDLPAR3 | |
| Water SCHEMBL28701484 | 0.77 | TPI1 (0.48) | TPI1PGK1PGK2PGDLPAR3 | |
| SCHEMBL7059626 | 0.77 | TPI1 (0.48) | TPI1PGK1PGK2PGDLPAR3 | |
| SCHEMBL29156118 | 0.77 | TPI1 (0.48) | TPI1PGK1PGK2PGDLPAR3 | |
| Hydrogen Peroxide SCHEMBL28079410 | 0.77 | TPI1 (0.48) | TPI1PGK1PGK2PGDLPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370438-A1 | IMIDAZO [1,2A]PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION | Exelixis, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2010065760-A1 | IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION | EXELIXIS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | S1PR1, S1PR5, S1PR3 | TPI1 2086/4885PGK1 1485/4885PGK2 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.